The EU's CHMP has adopted a positive opinion on Hospira's Nivestim (filgrastim; 12MU/0.2ml, 30MU/0.5mg, 48MU/0.5ml) solution for injection or infusion for the treatment of neutropenia. Nivestim is a biosimilar of Amgen's Neupogen which was the reference product for the application.
There are already filgrastim biosimilars marketed in various European countries; these include products from Sandoz (Novartis), Teva and Ratiopharm, each...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?